Expression profiling of FSHD-1 and FSHD-2 cells during myogenic differentiation evidences common and distinctive gene dysregulation patterns

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Cheli, Stefania ^a   François, Stephanie ^b   Bodega, Beatrice ^a,d   Ferrari, Francesco ^c   Tenedini, Elena ^c   Roncaglia, Enrica ^c   Ferrari, Sergio ^c   Ginelli, Enrico ^a   Meneveri, Raffaella ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d DULBECCO TELETHON INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2; MICRORNA; MUSCLE PROTEIN; MYOD1 PROTEIN; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG; FRG1 PROTEIN, HUMAN; FRG2 PROTEIN, HUMAN; NUCLEAR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CHILD; CHOLESTEROL SYNTHESIS; CHROMATIN STRUCTURE; CHROMOSOME 4Q; CONTROLLED STUDY; DEVELOPMENTAL GENE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 1 GENE; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY 2 GENE; FEMALE; GENE DISRUPTION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MUSCLE DEVELOPMENT; MYOBLAST; MYOTUBE; OXIDATIVE STRESS; PRESCHOOL CHILD; PROTEIN DEFECT; PROTEIN DEGRADATION; RNA METABOLISM; SCHOOL CHILD; CASE CONTROL STUDY; CELL LINE; CYTOLOGY; DNA MICROARRAY; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SKELETAL MUSCLE;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL LINE; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MUSCLE DEVELOPMENT; MUSCLE FIBERS, SKELETAL; MUSCULAR DYSTROPHY, FACIOSCAPULOHUMERAL; MYOBLASTS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 79958759071     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020966     Document Type: Article

References (46)

1. Tawil R, Van Der Maarel SM, (2006) Facioscapulohumeral muscular dystrophy. Muscle Nerve 34: 1-15.
2. Padberg GW, Lunt PW, Koch M, Fardeau M, (1991) Diagnostic criteria for facioscapulohumeral muscular dystrophy. Neuromuscul Disord 1: 231-4.
3. Padberg GW, Frants RR, Brouwer OF, Wijmenga C, Bakker E, et al. (1995) Facioscapulohumeral muscular dystrophy in the Dutch population. Muscle Nerve 2: S81-4.
4. Zatz M, Marie SK, Passos-Bueno MR, Vainzof M, Campiotto S, et al. (1995) High proportion of new mutations and possible anticipation in Brazilian facioscapulohumeral muscular dystrophy families. Am J Hum Genet 56 (1): 99-105.
5. van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, et al. (1993) FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 2 (12): 2037-42.
6. Lee JH, Goto K, Sahashi K, Nonaka I, Matsuda C, et al. (1995) Cloning and mapping of a very short (10-kb) EcoRI fragment associated with facioscapulohumeral muscular dystrophy (FSHD). Muscle Nerve 2: S27-31.
7. Lemmers RJ, Wohlgemuth M, van der Gaag KJ, van der Vliet PJ, van Teijlingen CM, et al. (2007) Specific sequence variations within the 4q35 region are associated with facioscapulohumeral muscular dystrophy. Am J Hum Genet 81 (5): 884-94.
8. Lemmers RJ, van der Vliet PJ, Klooster R, Sacconi S, Camano P, et al. (2010) A Unifying Genetic Model for Facioscapulohumeral Muscular Dystrophy. Science 329 (5999): 1650-3.
9. Gilbert JR, Stajich JM, Wall S, Carter SC, Qiu H, et al. (1993) Evidence for heterogeneity in facioscapulohumeral muscular dystrophy (FSHD). Am J Hum Genet 53 (2): 401-8.
10. de Greef JC, Lemmers RJ, van Engelen BG, Sacconi S, Venance SL, (2009) Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Hum Mutat 30 (10): 1449-59.
11. de Greef JC, Frants RR, van der Maarel SM, (2008) Epigenetic mechanisms of facioscapulohumeral muscular dystrophy. Mutat Res 647 (1-2): 94-102.
12. Dixit M, Ansseau E, Tassin A, Winokur S, Shi R, et al. (2007) DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc Natl Acad Sci (USA) 104 (46): 18157-62.
13. Bosnakovski D, Daughters RS, Xu Z, Slack JM, Kyba M, (2009) Biphasic myopathic phenotype of mouse DUX, an ORF within conserved FSHD-related repeats. PLoS One 4 (9): e7003.
14. Snider L, Asawachaicharn A, Tyler AE, Geng LN, Petek LM, et al. (2009) RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: new candidates for the pathophysiology of facioscapulohumeral dystrophy. Hum Mol Genet 18 (13): 2414-30.
15. Gabellin D, Green MR, Tupler R, (2002) Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 110 (3): 339-48.
16. Winokur ST, Chen YW, Masny PS, Martin JH Ehmsen JT, et al. (2003) Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation. Hum Mol Genet 12 (22): 2895-907.
17. Bodega B, Ramirez GD, Grasser F, Cheli S, Brunelli S, et al. (2009) Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation. BMC Biol 7: 41.
18. Engel AG, FranziniArmstrong C, eds. (2004) Myology, Basic and Clinical. Third edition, McGraw-Hill.
19. Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H, (2006) Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula. J Mol Med 84 (11): 901-10.
20. Dai M, Wang P, Boyd AD, Kostov G, Athey B, et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33 (20): e175.
21. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4 (1): 44-57.
22. Dennis G Jr, Sherman BT, Hosak DA, Yang J Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4 (5): P3.
23. Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z, (2009) GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 10: 48.
24. de Greef JC, Lemmers RJ, Camano P, Day JW, Sacconi S, et al. (2010) Clinical features of facioscapulohumeral muscular dystrophy 2. Neurology 75 (17): 1548-54.
25. Arashiro P, Eisemberg I, Kho AT, Cerqueira AM, Canovas M, et al. (2009) Transcriptional regulation differs in affected facioscapulohumeral muscular dystrophy patients compared to asymptomatic related carriers. Proc Natl Acad Sci (USA) 106 (15): 6220-5.
26. Winokur ST, Barrett K, Martin JH, Forrester JR, Simon M, et al. (2003) Facioscapulohumeral muscular dystrophy (FSHD) myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscul Disord 13 (4): 322-33.
27. Osborne RJ, Welle S, Venance SL, Thornrnton CA, Tawil R, (2007) Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 68 (8): 569-77.
28. Collins CA, Gnocchi VF, White RB, Boldrin L, Prez-Riuz A, et al. (2009) Integrated functions of Pax3 and Pax7 in the regulation of proliferation, cell size and myogenic differentiation. PLoS One 4 (2): e4475.
29. Maroto M, Reshef R, Munsterberg AE, Koester S, Goulding M, et al. (1997) Ectopic Pax-3 activates MyoD and Myf-5 expression in embryonic mesoderm and neural tissue. Cell 89 (1): 139-48.
30. Ridgeway AG, Skerjanc IS, (2001) Pax3 is essential for skeletal myogenesis and the expression of Six1 and Eya2. J Biol Chem 276 (22): 19033-9.
31. Epstein JA, Lam P, Jepeal L, Maas RL, Shapiro DN, (1995) Pax3 inhibits myogenic differentiation of cultured myoblast cells. J Biol Chem 270 (20): 11719-22.
32. Miller PJ, Hollenbach AD, (2007) The oncogenic fusion protein Pax3-FKHR has a greater post-translational stability relative to Pax3 during early myogenesis. Biochim Biophys Acta 1770 (10): 1450-8.
33. De Falco G, Comes F, Simone C, (2006) pRb: master of differentiation. Coupling irreversible cell cycle withdrawal with induction of muscle-specific transcription. Oncogene 25 (38): 5244-9.
34. Zeng W, de Greef JC, Chen YY, Chien R, Kong X, et al. (2009) Specific loss of histone H3 lysine 9 trimethylation and HP1gamma/cohesin binding at D4Z4 repeats is associated with facioscapulohumeral dystrophy (FSHD). PLoS Genet 5 (7): e1000559.
35. Thomas JO, (2001) HMG1 and 2: architectural DNA-binding proteins. Biochem Soc Trans 29(Pt 4): 395-401.
36. Rusconi F, Mancinelli E, Colombo G, Cardani R, Da Riva L, et al. (2010) Proteome profile in Myotonic Dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways. Neurobiol Dis 38 (2): 273-80.
37. Kramerova I, Kudryashova E, Wu B, Germain S, Vandenborne K, et al. (2009) Mitochondrial abnormalities, energy deficit and oxidative stress are features of calpain 3 deficiency in skeletal muscle. Hum Mol Genet 18 (17): 3194-205.
38. Huichalaf C, Schoser B, Schneider-Gold C, Jin B, Sarkar P, et al. (2009) Reduction of the rate of protein translation in patients with myotonic dystrophy 2. J Neurosci 29 (28): 9042-9.
39. Salisbury E, Schoser B, Schneider-Gold C, Wang GL, Huichalaf C, et al. (2009) Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients. Am J Pathol 175 (2): 748-62.
40. Li W, Wu G, Wan Y, (2007) The dual effects of Cdh1/APC in myogenesis. FASEB J 21 (13): 3606-17.
41. Simons K, Ikonen E, (2000) How cells handle cholesterol. Science 290 (5497): 1721-6.
42. Volonte D, Peoples AJ, Galbiati F, (2003) Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C. Mol Biol Cell 14 (10): 4075-88.
43. Gazzerro E, Sotgia F, Bruno C, Lisanti MP, Minetti C, (2010) Caveolinopathies: from the biology of caveolin-3 to human diseases. Eur J Hum Genet 18 (2): 137-45.
44. Barro M, Carnac G, Flavier S, Mercier J, Vassetzky Y, et al. (2010) Myoblasts from affected and non-affected FSHD muscles exhibit morphological differentiation defects. J Cell Mol Med 14 (1-2): 275-89.
45. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, et al. (2006) The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 38 (2): 228-33.
46. Eisenberg I, Eran A, Nishino I, Moggio M, Lamperti C, et al. (2007) Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci (USA) 104 (43): 17016-21.